{"id":"W2807386738","doi":"10.1002/pros.23662","title":"A dose finding clinical trial of cabozantinib (XL184) administered in combination with abiraterone acetate in metastatic castration‐resistant prostate cancer","year":2018,"lang":"en","type":"article","venue":"The Prostate","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"McMaster University","funders":"National Cancer Institute; Exelixis","keywords":"Medicine; Cabozantinib; Abiraterone acetate; Prostate cancer; Tolerability; Cohort; Internal medicine; Urology; Oncology; Cabazitaxel; Prednisone; Cancer; Adverse effect; Androgen deprivation therapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001731121,0.0002393109,0.0006126513,0.0002584151,0.0000966314,0.00004654079,0.0001496404,0.00005979297,0.0000553209],"category_scores_gemma":[0.0001176457,0.0001404505,0.00007031759,0.0007455794,0.0006045449,0.0001847986,0.00006266152,0.0003660883,0.00001387531],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001228607,"about_ca_system_score_gemma":0.0008292426,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006511307,"about_ca_topic_score_gemma":0.003154039,"domain_scores_codex":[0.9972271,0.0003856052,0.0009738606,0.0004120088,0.000483159,0.0005182654],"domain_scores_gemma":[0.9986833,0.0001901705,0.0003676125,0.0003822836,0.0002606407,0.0001160178],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.78551,0.003990905,0.1385302,0.0008093294,0.0005678978,0.0007026549,0.02254322,0.00005373593,0.01574832,0.0002531729,0.0002066414,0.03108395],"study_design_scores_gemma":[0.516831,0.02948617,0.4184485,0.002140199,0.00043681,0.00005147589,0.002146226,0.001964805,0.0257727,0.001190168,0.0009361309,0.0005957885],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9919168,0.0002690777,0.000006369792,0.003060117,0.0001829762,0.004092065,0.00007172659,0.00003099398,0.0003698235],"genre_scores_gemma":[0.996382,0.0005367459,0.0003325471,0.00008573206,0.00007110164,0.0004963402,0.00006051054,0.0000374011,0.001997633],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2799183,"threshold_uncertainty_score":0.5727404,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1291539729666525,"score_gpt":0.434792639625811,"score_spread":0.3056386666591585,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}